Ticho Barry 4

What Happened
Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), sold 2,243 shares in an open-market transaction on May 1, 2026, at $32.79 per share, generating proceeds of $73,548. This was a sale (not a purchase), which is generally considered routine insider selling rather than a direct bullish signal.

Key Details

• Transaction date: 2026-05-01; Price per share: $32.79; Shares sold: 2,243; Total proceeds: $73,548.
• Filing date (Form 4): 2026-05-05; Period of report: 2026-05-01. (Timeliness of filing not indicated in the provided excerpt.)
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: Transaction executed under a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.

Context
A 10b5-1 plan means the sale followed pre-established instructions, which can make the trade more routine and less indicative of inside knowledge. For retail investors, purchases typically convey clearer insider confidence than routine sales; treat this single sale as factual data rather than a signal of company prospects.